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Salvador Moncada — whose work on
the signalling molecule nitric oxide
has made him one of biomedicine’s
most cited scientists — was once
described by his boss as capable of
running not just an excellent
department but also a country. The
time was the late 1970s and the boss
was James Black, later to become a
Nobel prizewinner. Both men were
at the research laboratories of the
pharmaceutical company Wellcome,
now GlaxoWellcome.
Today, with more than 500
published papers and membership of
the Royal Society and the National
Academy of Sciences of the USA
under his belt, Moncada’s air of
command is no less apparent. He
might not be running a country but,
as Director of the new Wolfson
Institute for Biomedical Research at
University College, London, the
Honduran-born pharmacologist
clearly still relishes working at the
forefront of a research field that is
expanding at an unprecedented rate.
Nitric oxide (NO), a gas once
famous only for being an air pollutant,
has emerged over the past dozen
years as a physiologically vital
molecule with a bewilderingly broad
range of functions. It acts as a
vasodilator, released constantly by the
cells lining the walls of blood vessels
and central to the maintenance of
vessel tone and normal blood
pressure. It is released by activated
macrophages to kill infected cells and
tumour cells. And it appears in certain
neuronal pathways involved in
learning and memory. It might be
responsible for the increased blood
flow that is often seen on PET scans
in areas of the brain where neuronal
activity is increased. So diverse are
NO’s functions that Moncada
believes it must have evolved at a
primitive stage of life. “We have
found NO-positive neurons in the
brain of the locust, and NO has also
been identified in Drosophila.” 
Back in 1980, Robert Furchgott
at the State University of New York
and others observed that endothelial
cells release a substance that relaxes
vascular smooth muscle. In 1987
Moncada reported in Nature that
this substance, known until then as
endothelium-derived relaxing factor
(EDRF), is in fact NO. Moncada’s
group went on to show that NO is
made from an amino acid,
L-arginine, using an
enzyme called nitric
oxide synthase. The
findings unleashed a
torrent of papers on NO,
with about 20,000
appearing since 1987.
Yet, to the surprise of
many, when last year’s
Nobel prize for physiology
or medicine was awarded
for work on NO as a
signalling molecule in the
cardiovascular system,
Moncada was not among the
prizewinners. The three recipients of
the prize are all pharmacologists based
in the US: Furchgott, Louis Ignarro
at the University of California, Los
Angeles, and Ferid Murad at the
University of Texas, Houston.
The decision has proved highly
controversial, and Moncada has no
shortage of powerful supporters.
“My feeling is that he was as
deserving of it as any of us,” says
Furchgott. “He really developed the
field of nitric oxide more than
anyone else.” John Vane, another
Nobel prizewinner and former
colleague, is equally supportive.
“He is pretty well king of the field,
except that he has not been
crowned.”
Moncada, who has two thick files
of letters of support from other
scientists who, he says, protested at
the decision, chooses his words with
care. “Any institution can give prizes
to whoever they want … A different
story is to ask what are the seminal
contributions that create a field of
research, and in that respect the
scientific community, which
conducts peer review, has already
given a verdict. I am very happy
about our own contribution. I have
had recognition from many
institutions for the discovery of the
role of nitric oxide and the L-arginine
pathway, including the National
Academy of Sciences of the USA.”
Not surprisingly, however, there is
disagreement about who should have
credit for what. Some in the field say
that Ignarro had carried out work that
reached the same
conclusion as Moncada at
an earlier date, although
publication of Ignarro’s
work came six months
later. Others say that
Moncada’s work, though
central to the nitric oxide
story, simply investigated
others’ hunches and,
indeed, Moncada’s 1987
paper itself explicitly
acknowledges Furchgott’s
earlier suggestion that
EDRF might be NO.
In a culture that expects its
academics to be self-deprecating,
Moncada’s robust defence of his own
contribution has strained some
friendships. But from his perspective
as a scientist from a developing
country, he considers that defence to
be necessary, even an obligation.
Moncada is loyal to his Latin
American origins and considers it his
responsibility to support others from
the developing world who may lose
out in a competitive field merely
because of, say, their poor command
of English. “If a Latin American
manages to get where I am he must
be conscious that he has to help
other people who are disadvantaged.”
Moncada was born in Tegucigalpa
in 1944, the son of an Honduran
doctor. His mother was a Jew of
German origin who left Europe for
Central America at the beginning of
the second world war. After medical
school, he came to England in 1971
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through what he calls a string of
coincidences. A physiologist
colleague in Guatemala who
happened to have worked with John
Vane, then at the Royal College of
Surgeons, recommended Moncada to
Vane. Once in England, Moncada
joined Vane’s team, which was then
working on the mechanism of action
of aspirin and its relationship with
prostaglandin synthesis.
In 1974, he returned to Honduras
to pursue a research career there,
inspired by what he now says was a
“romantic view” of doing science in a
poor country. Finding it impossible
without the necessary infrastructure,
he lasted in Honduras only a year. By
1975 Moncada was back working
with Vane, who by this time was at
Wellcome. Moncada is immensely
grateful for Vane’s generosity. Vane
— now at the William Harvey
Research Institute within the
University of London — says
Moncada is “outstandingly brilliant”,
and that his qualities were evident
almost from the start. By 1986,
Moncada had become director of
research at the Wellcome
laboratories.
If the public field has had its
frustrations, there have recently been
personal delights for Moncada. He
has married for the second
time — and, whereas he may be an
uncrowned king in biomedicine, his
wife is a real princess. Esmeralda, a
member of the Belgian Royal Family
and a journalist, gave birth to a baby
daughter last year. 
Even new parenthood, however,
has not displaced his enthusiasm for
his research. His latest interest is in
the process by which nitric oxide’s
normal physiological functions are
subverted in disease;
mitochondria — which he believes
might be centrally implicated in that
process — are the latest target for his
team’s intense investigations. All this
makes running a country sound
rather dull by comparison.
Phyllida Brown is a science writer based in
London.
The cells of diatoms — unicellular
aquatic phytoplankton — are
constructed like a pill box of glass; the
outer wall of each cell is made of
hydrated silica, with an inner pectic
layer enclosing the cytoplasm.
Floating diatoms have several
adaptations to keep them near the
surface. For example, the star-
shaped cells of Asterionella formosa
shown above contain small oil drops
that help to keep the cells in
suspension. In other species, such as
Biddulphia sinensis (above right),
each cell has four long horns, which
increase surface resistance.
These photomicrographs of live
diatoms were kindly provided by Jan
Parmentier. There are more
examples on his website at
http://www.euronet.nl/users/janpar/index.html
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